Our Lead Product in Renal Orphan Diseases
distal Renal Tubular Acidosis (dRTA) – A Renal Orphan Disease
ADV7103 is a combination product that contains two active pharmaceutical ingredients specifically formulated as 2mm granules. This dosage form is designed to maximize the absorption of the product over a 12-hour period, hence allowing twice a day treatment. ADV7103 is tasteless and easy to administer orally in either young children or adults.
ADV7103 was granted Orphan Drug Designation by the EU for the treatment of dRTA in June 2017.
ADV7103 is also being developed for the treatment of a second indication, Cystinuria, an inherited renal tubulopathy.